Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2022

Open Access 01-12-2022 | Research article

Sustained correction of hippocampal neurogenic and cognitive deficits after a brief treatment by Nutlin-3 in a mouse model of fragile X syndrome

Authors: Sahar Javadi, Yue Li, Jie Sheng, Lucy Zhao, Yao Fu, Daifeng Wang, Xinyu Zhao

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Background

Fragile X syndrome (FXS), the most prevalent inherited intellectual disability and one of the most common monogenic forms of autism, is caused by a loss of fragile X messenger ribonucleoprotein 1 (FMR1). We have previously shown that FMR1 represses the levels and activities of ubiquitin ligase MDM2 in young adult FMR1-deficient mice, and treatment by a MDM2 inhibitor Nutlin-3 rescues both hippocampal neurogenic and cognitive deficits in FMR1-deficient mice when analyzed shortly after the administration. However, it is unknown whether Nutlin-3 treatment can have long-lasting therapeutic effects.

Methods

We treated 2-month-old young adult FMR1-deficient mice with Nutlin-3 for 10 days and then assessed the persistent effect of Nutlin-3 on both cognitive functions and adult neurogenesis when mice were 6-month-old mature adults. To investigate the mechanisms underlying the persistent effects of Nutlin-3, we analyzed the proliferation and differentiation of neural stem/progenitor cells isolated from these mice and assessed the transcriptome of the hippocampal tissues of treated mice.

Results

We found that transient treatment with Nutlin-3 of 2-month-old young adult FMR1-deficient mice prevents the emergence of neurogenic and cognitive deficits in mature adult FXS mice at 6 months of age. We further found that the long-lasting restoration of neurogenesis and cognitive function might not be mediated by changing intrinsic properties of adult neural stem cells. Transcriptomic analysis of the hippocampal tissue demonstrated that transient Nultin-3 treatment leads to significant expression changes in genes related to the extracellular matrix, secreted factors, and cell membrane proteins in the FMR1-deficient hippocampus.

Conclusions

Our data indicates that transient Nutlin-3 treatment in young adults leads to long-lasting neurogenic and behavioral changes likely through modulating adult neurogenic niche that impact adult neural stem cells. Our results demonstrate that cognitive impairments in FXS may be prevented by an early intervention through Nutlin-3 treatment.
Appendix
Available only for authorised users
Literature
1.
Tassone F, Iong KP, Tong T-H, Lo J, Gane LW, Berry-Kravis E, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2013;4(12):1–13.
2.
3.
Kaufmann WE, Kidd SA, Andrews HF, Budimirovic DB, Esler A, Haas-Givler B, et al. Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment. Pediatrics. 2017;139(Supplement 3):S194–206.CrossRefPubMed
4.
Pieretti M, Zhang F, Fu Y-H, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817–22.CrossRefPubMed
5.
Verkerk AJ, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–14.CrossRefPubMed
6.
De Rubeis S, Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: insights into mRNA stability. Mol Cell Neurosci. 2010;43(1):43–50.CrossRefPubMed
7.
8.
9.
Kurosaki T, Imamachi N, Proschel C, Mitsutomi S, Nagao R, Akimitsu N, et al. Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay. Nat Cell Biol. 2021;23(1):40–8.CrossRefPubMedPubMedCentral
10.
Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, Blanco A, Chen S, Stützer A, et al. A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell. 2014;157(4):869–81.CrossRefPubMedPubMedCentral
11.
12.
13.
Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015;16(10):595–605.CrossRefPubMedPubMedCentral
14.
Ascano M, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. 2012;492(7429):382–6.CrossRefPubMedPubMedCentral
15.
Dansie LE, Phommahaxay K, Okusanya AG, Uwadia J, Huang M, Rotschafer SE, et al. Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice. Neuroscience. 2013;246:186–98.CrossRefPubMed
16.
17.
Bakker CE, de Diego OY, Bontekoe C, Raghoe P, Luteijn T, Hoogeveen AT, et al. Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res. 2000;258(1):162–70.CrossRefPubMed
18.
Devys D, Lutz Y, Rouyer N, Bellocq J-P, Mandel J-L. The FMR–1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet. 1993;4(4):335–40.CrossRefPubMed
19.
Luo Y, Shan G, Guo W, Smrt RD, Johnson EB, Li X, et al. Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet. 2010;6(4).
20.
Li Y, Stockton ME, Bhuiyan I, Eisinger BE, Gao Y, Miller JL, et al. MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome. Sci Transl Med. 2016;8(336):336ra61.CrossRefPubMedPubMedCentral
21.
Li Y, Stockton ME, Eisinger BE, Zhao Y, Miller JL, Bhuiyan I, et al. Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome. Nat Commun. 2018;9(1):1–16.
22.
Guo W, Allan AM, Zong R, Zhang L, Johnson EB, Schaller EG, et al. Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med. 2011;17(5):559–65.CrossRefPubMedPubMedCentral
23.
Liu B, Li Y, Stackpole EE, Novak A, Gao Y, Zhao Y, et al. Regulatory discrimination of mRNAs by FMRP controls mouse adult neural stem cell differentiation. Proc Natl Acad Sci. 2018;115(48):E11397–E405.CrossRefPubMedPubMedCentral
24.
Pinar C, Yau S-y, Sharp Z, Shamei A, Fontaine CJ, Meconi AL, et al. Effects of voluntary exercise on cell proliferation and neurogenesis in the dentate gyrus of adult FMR1 knockout mice. Brain Plast. 2018;4(2):185–95.CrossRefPubMedPubMedCentral
25.
Lazarov O, Demars MP, Da Tommy ZK, Ali HM, Grauzas V, Kney A, et al. Impaired survival of neural progenitor cells in dentate gyrus of adult mice lacking fMRP. Hippocampus. 2012;22(6):1220–4.CrossRefPubMed
26.
Eadie B, Zhang W, Boehme F, Gil-Mohapel J, Kainer L, Simpson J, et al. Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus. Neurobiol Dis. 2009;36(2):361–73.CrossRefPubMed
27.
Kempermann G, Song H, Gage FH. Neurogenesis in the adult hippocampus. Cold Spring Harbor Perspect Biol. 2015;7(9):a018812.CrossRef
28.
Eisch AJ, Cameron HA, Encinas JM, Meltzer LA, Ming G-L, Overstreet-Wadiche LS. Adult neurogenesis, mental health, and mental illness: hope or hype? J Neurosci. 2008;28(46):11785–91.CrossRefPubMedPubMedCentral
29.
Babcock KR, Page JS, Fallon JR, Webb AE. Adult hippocampal neurogenesis in aging and Alzheimer’s disease. Stem Cell Rep. 2021;16(4):681–93.CrossRef
30.
Consortium TD-BFX. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell. 1994;78(1):23–33.
31.
Yamaguchi M, Saito H, Suzuki M, Mori K. Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice. Neuroreport. 2000;11(9):1991–6.CrossRefPubMed
32.
Guo W, Zhang L, Christopher DM, Teng Z-Q, Fausett SR, Liu C, et al. RNA-binding protein FXR2 regulates adult hippocampal neurogenesis by reducing Noggin expression. Neuron. 2011;70(5):924–38.CrossRefPubMedPubMedCentral
33.
34.
Contestabile A, Greco B, Ghezzi D, Tucci V, Benfenati F, Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Investig. 2012;123(1).
35.
Guo W, Patzlaff NE, Jobe EM, Zhao X. Isolation of multipotent neural stem or progenitor cells from both the dentate gyrus and subventricular zone of a single adult mouse. Nat Protoc. 2012;7(11):2005.CrossRefPubMedPubMedCentral
36.
Gao Y, Shen M, Gonzalez JC, Dong Q, Kannan S, Hoang JT, et al. RGS6 mediates effects of voluntary running on adult hippocampalneurogenesis. Cell Rep. 2020;32(5):107997.
37.
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.CrossRefPubMedPubMedCentral
38.
Walter W, Sanchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–4.CrossRefPubMed
39.
Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47(W1):W212–W24.CrossRefPubMedPubMedCentral
40.
Kempermann G, Jessberger S, Steiner B, Kronenberg G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 2004;27(8):447–52.CrossRefPubMed
41.
Guo W, Murthy AC, Zhang L, Johnson EB, Schaller EG, Allan AM, et al. Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet. 2012;21(3):681–91.CrossRefPubMed
42.
Eisinger BE, Zhao X. Identifying molecular mediators of environmentally enhanced neurogenesis. Cell Tissue Res. 2018;371(1):7–21.CrossRefPubMed
43.
44.
45.
46.
Kjell J, Fischer-Sternjak J, Thompson AJ, Friess C, Sticco MJ, Salinas F, et al. Defining the adult neural stem cell niche proteome identifies key regulators of adult neurogenesis. Cell Stem Cell. 2020;26(2):277–93. e8.CrossRefPubMedPubMedCentral
47.
48.
Ziegler AN, Feng Q, Chidambaram S, Testai JM, Kumari E, Rothbard DE, et al. Insulin-like growth factor II: an essential adult stem cell niche constituent in brain and intestine. Stem Cell Rep. 2019;12(4):816–30.CrossRef
49.
Sutcu HH, Ricchetti M. Loss of heterogeneity, quiescence, and differentiation in muscle stem cells. Stem Cell Invest. 2018;5.
50.
Stevanovic M, Drakulic D, Lazic A, Ninkovic DS, Schwirtlich M, Mojsin M. SOX transcription factors as important regulators of neuronal and glial differentiation during nervous system development and adult neurogenesis. Front Mol Neurosci. 2021;14:51.CrossRef
51.
Francois M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, et al. Sox18 induces development of the lymphatic vasculature in mice. Nature. 2008;456(7222):643–7.CrossRefPubMed
52.
Shimozaki K, Clemenson GD, Gage FH. Paired related homeobox protein 1 is a regulator of stemness in adult neural stem/progenitor cells. J Neurosci. 2013;33(9):4066–75.CrossRefPubMedPubMedCentral
53.
Panman L, Andersson E, Alekseenko Z, Hedlund E, Kee N, Mong J, et al. Transcription factor-induced lineage selection of stem-cell-derived neural progenitor cells. Cell Stem Cell. 2011;8(6):663–75.CrossRefPubMed
54.
Silva AC, Pereira C, Fonseca ACR, Pinto-do-Ó P, Nascimento DS. Bearing my heart: the role of extracellular matrix on cardiac development, homeostasis, and injury response. Front Cell Dev Biol. 2021;8:1705.CrossRef
55.
Hall BK, Miyake T. All for one and one for all: condensations and the initiation of skeletal development. Bioessays. 2000;22(2):138–47.CrossRefPubMed
56.
Hu H, Lin S, Wang S, Chen X. The role of transcription factor 21 in epicardial cell differentiation and the development of coronary heart disease. Front Cell Dev Biol. 2020;8:457.CrossRefPubMedPubMedCentral
57.
Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2018;17(4):280–99.CrossRefPubMed
58.
Tranfaglia MR, Thibodeaux C, Mason DJ, Brown D, Roberts I, Smith R, et al. Repurposing available drugs for neurodevelopmental disorders: the fragile X experience. Neuropharmacology. 2019;147:74–86.CrossRefPubMed
59.
Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des. 2011;17(6):569–77.CrossRefPubMed
60.
Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene. 2013;32(43):5129–43.CrossRefPubMed
61.
Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harbor Perspect Biol. 2010;2(8):a000935.CrossRef
62.
Sheikh T, Sen E. p53 affects epigenetic signature on SOCS1 promoter in response to TLR4 inhibition. Cytokine. 2021;140:155418.CrossRefPubMed
63.
Tovy A, Spiro A, McCarthy R, Shipony Z, Aylon Y, Allton K, et al. p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneity. Genes Dev. 2017;31(10):959–72.CrossRefPubMedPubMedCentral
64.
65.
Kempermann G. Seven principles in the regulation of adult neurogenesis. Eur J Neurosci. 2011;33(6):1018–24.CrossRefPubMed
66.
Kandasamy M, Lehner B, Kraus S, Sander PR, Marschallinger J, Rivera FJ, et al. TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. J Cell Mol Med. 2014;18(7):1444–59.CrossRefPubMedPubMedCentral
67.
Bond AM, Peng CY, Meyers EA, McGuire T, Ewaleifoh O, Kessler JA. BMP signaling regulates the tempo of adult hippocampal progenitor maturation at multiple stages of the lineage. Stem Cells. 2014;32(8):2201–14.CrossRefPubMed
68.
Metadata
Title
Sustained correction of hippocampal neurogenic and cognitive deficits after a brief treatment by Nutlin-3 in a mouse model of fragile X syndrome
Authors
Sahar Javadi
Yue Li
Jie Sheng
Lucy Zhao
Yao Fu
Daifeng Wang
Xinyu Zhao
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02370-9

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue

Research article

Empirical evidence of study design biases in nutrition randomised controlled trials: a meta-epidemiological study

Research article

Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Research article

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Research article

Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs

Research article

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study

Research article

Dietary fibre in hypertension and cardiovascular disease management: systematic review and meta-analyses